Since our study, new HF therapies have been developed, namely the angiotensin receptor-neprilysin and sodium glucose co-transporter 2 (SGLT2) inhibitors, which have proven to be effective in reducing risk of HF hospitalisation and mortality in patients with chronic HF and reduced ejection fraction (HFrEF) [2, 3]. Here, SLC5A2 is linked to hydrops fetalis.